Display Settings:

Format

Send to:

Choose Destination

    Br J Ophthalmol. 2004 Nov;88(11):1425-8.

    Mitomycin C for pterygium: long term evaluation.

    Raiskup F, Solomon A, Landau D, Ilsar M, Frucht-Pery J.

    Department of Ophthalmology, Hadassah University Hospital, Jerusalem, Israel.

    AIM: To evaluate long term complications after pterygium excision with mitomycin C (MMC) application. DESIGN: Prospective non-comparative interventional case series. PARTICIPANTS: Ninety nine patients who underwent pterygium surgery and participated in a controlled study for efficacy of MMC for pterygium surgery between 1989 and 1994. METHODS: Patients who were located and agreed to come for examination underwent a complete eye examination. The bare sclera area, in particular, was examined for possible complications. The main outcome measures were anatomical findings in area of MMC application. RESULTS: Forty three eyes of 43 patients were examined. Sixty three per cent of patients had pterygium surgery with intraoperative application of 0.02% MMC for 5 minutes and 37% of patients received MMC 1% or 2% drops four times daily for 2 weeks postoperatively. In three patients, pterygium recurred within 18 months. The only complication was mild conjunctival avascularity in areas of pterygium excision in 30% of patients. CONCLUSION: Long term evaluation revealed that the use of MMC in pterygium surgery is safe, but for a strict selection of patients, controlled use of MMC and long term follow up are required.

    PMID: 15489487 [PubMed - indexed for MEDLINE]

    PMCID: 1772401

    Supplemental Content

    Click here to read Click here to read

    Patient drug information

    • Mitomycin (Mutamycin®)

      Your doctor has ordered the drug mitomycin to help treat your illness. The drug is given by injection into a vein.